The Pediatric MATCH Screening Trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Clinical Trial Information
Trial Contact: Spinelli, Jennifer; Parker, Melanie; Armatti, Julie M; Doyle, Katherine M; Dubberly, Paige D
Trial Phone: 321.841.5357 ; 321-843-1036 ; 321-843-5284 ; 3218412008 ; 321-841-7561
IRB No: APEC1621SC
Protocol Abbrev: APEC1621SC
Principal Investigator: Amy A. Smith, MD
Phase: Drug: Phase II
Age Group: Adult;Pediatric
Secondary Protocol No: APEC1621SC
Treatment: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Mutation Carrier Screening
ClinicalTrials.gov ID: NCT03155620
I. To utilize clinical and biological data to screen for eligibility to phase 2 pathway-targeting specific subprotocols of pathway-targeting agents in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders.
II. To determine the proportion of pediatric patients whose advanced tumors have pathway alterations that can be targeted by select anti-cancer drugs.
III. To determine the objective response rates (ORR; complete response + partial response) in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders harboring a priori specified genomic alterations treated with pathway-targeting agents.
Sexes Eligible for Study - All
Ages - 12 Months to 21 Years (Child, Adult)
Accepts Healthy Volunteers - No